BioWorld Asia

Jan. 23, 2008

Novexel Receives €75M Up Front for Beta Lactamase Inhibitor

Novexel SA and Forest Laboratories Holdings Ltd., a wholly owned subsidiary of Forest Laboratories Inc. signed an agreement allowing the U.S. company to develop, manufacture and commercialize Novexel's novel intravenous beta lactamase inhibitor, NXL104, in combination with Forest's ceftaroline. (BioWorld International) Read More

UK Research Groups Get OK for Human/Animal Cloned Embryos

Cancer-Killing Viruses Target Metastases from Primary Tumors

Scil, Pfizer Enter $250M Deal for Preclinical Osteo Drug

First Index Fund to Focus on Large-Scale Investments

Other News To Note

European Drug Industry Faces Antitrust Bust on Generics

Vivendy Raises $15.5M for Morbus Morquio Therapy

UK Start-Ups Launch Campaign Opposing VC Sales Tax Boost

Today's news in brief

BioWorld

BioWorld briefs for Feb. 6, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...

Serotonin receptor modulators for the treatment of OUD

BioWorld Science

Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...